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Objectives: To characterize CTX-M-12 extended-spectrum b-lactamase (ESBL) produced by clinical
Escherichia coli isolates and to investigate its genetic environment.
Methods: Antimicrobial susceptibilities were determined by disc diffusion and agar dilution methods,
and the double-disc synergy test was carried out. Detection of genes encoding class A b-lactamases
was performed by PCR amplification, and the genetic environments of the blaCTX-M-12 genes were
investigated by PCR and sequencing of the regions surrounding the genes. Kinetic parameters were
determined from purified CTX-M-12.
Results: Sequence data for the CTX-M-1 cluster from three clinical E. coli isolates indicated the presence
of CTX-M-12. An ISEcp1 insertion sequence was located 49 bp upstream of blaCTX-M-12 in all three E. coli
isolates. CTX-M-12 had a more potent hydrolytic activity against cefotaxime than against ceftazidime
and was encoded on a self-transferable 18 kbp plasmid.
Conclusions: This work shows that CTX-M-12, which confers high-level resistance to cefotaxime but
not to ceftazidime, has emerged in Korea. The blaCTX-M-12 gene was associated with an upstream
ISEcp1 insertion sequence.
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Introduction
CTX-M-type extended-spectrum b-lactamases (ESBLs), the most
widespread enzymes among non-TEM and non-SHV plasmid-
mediated ESBLs, were initially reported in the second half of the
1980s in Europe.1 At present, the CTX-M family comprises more
than 50 enzymes that have greater hydrolytic activity against
cefotaxime than ceftazidime. In Korea, CTX-M-15 and CTX-M-3
were reported to be the most prevalent ESBLs in clinical
Escherichia coli isolates in a surveyof 12Koreanhospitals in 2003.2
CTX-M-12 ESBL was first detected from Klebsiella
pneumoniae isolates from an outbreak among six newborn
babies in Kenya in 2001.3 And then, the ESBL was also detected
from a clinical K. pneumoniae isolate from Colombia and from
a clinical E. coli isolate from China.4,5 CTX-M-12 differs from
CTX-M-3, the nearest CTX-M neighbour, by three amino acid
substitutions along with five silent point changes.
The ISEcp1 element is able to achieve the transfer of the
downstream DNA sequence by a one-ended transposition
process.1 This element has repeatedly been observed upstream
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of ORFs encoding the CTX-M enzymes. In the present study, we
report the first isolation of CTX-M-12 ESBL from three clinical
E. coli isolates from Korea. Additionally, we have characterized
the genetic environment of the blaCTX-M-12 genes and have
measured kinetic parameters of CTX-M-12.
Materials and methods
Bacterial strains
Clinical isolates of E. coli were identified with the VITEK system
(bioMe´rieux, Marcy l’Etoile, France). E. coli BL21(DE3) was the
host for cloning experiments. E. coli J53 AzideR and E. coli ATCC
25933 were used as a recipient strain for conjugative transfer and
an MIC reference strain, respectively.
Antimicrobial susceptibility testing and mating-out assays
Antimicrobial susceptibilities were determined by disc diffusion
and agar dilution methods according to the recommendations of the
CLSI.6,7 MICs of b-lactams were determined alone or in combina-
tion with a fixed concentration of clavulanic acid (4 mg/L). ESBL-
production was detected by the double-disc synergy (DDS) test.8
Conjugation experiments were carried out as described previously.2
PCR experiments
Searches for genes coding for class A ESBLs were performed by PCR
amplification.2 The templates for PCR amplification in clinical
isolates were a whole-cell lysate. The PCR products were subjected to
direct sequencing. Both strands of each PCR product were sequenced
twice with an automatic sequencer (model 373A; Applied Bio-
systems, Weiterstadt, Germany). The genetic organization of the
blaCTX-M-12 gene was investigated by PCR and sequencing of the
regions surrounding this gene.
Purification of CTX-M-12 b-lactamase
The PCR product obtained with the primers CTX-M-12 pcrF (50-GG
GAA TTC CAT ATG GTT AAA AAA TCA CTG CG-30; NdeI site
underlined) and CTX-M-12 pcrR (50-CCG CTC GAG CAA ACC
GTC GGT GAC GAT TTT-30; XhoI site underlined) was purified
with a QIAquick column (Qiagen, Courtaboeuf, France) and ligated
in the NdeI and XhoI sites of pET30a (Novagen, Milan, Italy). The
resultant pET30a-CTX-M-12 expression construct was transformed
into E. coli BL21(DE3). LB broth (1 L) supplemented with
kanamycin (50 mg/L) was cultured at 37C. Isopropyl-b-D-
thiogalactopyranoside (final concentration 0.4 mM) was added
when the culture reached an A600 of 0.6, and the culture was
incubated overnight at 20C. The cells were harvested by centrifuga-
tion and resuspended in 50 mL of buffer A [50 mM Tris (pH 7.0),
500 mM NaCl, 10 mM imidazole]. Cells were disrupted in a
microfluidizer (at 15 000 psi) and the lysate centrifuged at 15 000 g
for 40 min. The supernatant was loaded onto a Ni-NTA column
(XK16, Amersham-Pharmacia-Biosciences, Milan, Italy) pre-
equilibrated with buffer A, and washed with buffer B [50 mM Tris
(pH 7.0), 500 mM NaCl, 25 mM imidazole]. The b-lactamase was
eluted with a linear gradient of imidazole (25–300 mM in 1 h). The
fractions containing nitrocefin-hydrolysing activity (purity-confirmed
by SDS–PAGE) were pooled and dialysed with buffer C [50 mM Tris
(pH 7.0), 300 mM NaCl without imidazole]. The final protein
concentration was 3 mg/mL (purity 98%).
Isoelectric focusing (IEF)
To determine the isoelectric point (pI), 5 mL of the condensed
supernatant containing b-lactamase was loaded onto a Novex IEF Gel
(pH 3–10; Invitrogen, Carlsbad, CA, USA) with a Xcell surelock
Mini-Cell system (Invitrogen). Running conditions were 100 V
constant for 1 h, 200 V constant for 1 h and 500 V for 30 min.2
The pI of the b-lactamase was measured by staining the gel with a
0.05% solution of nitrocefin (Oxoid, Basingstoke, UK).
Kinetic measurements
Purified b-lactamase was used for kinetic measurements performed
at 30C with 100 mM sodium phosphate buffer (pH 7.0) with a
Cary 300 Bio UV-visible spectrophotometer (Varian Inc., Palo Alto,
CA, USA). Extinction coefficients of each antibiotic substrate used
in the spectrophotometric assays were the same as described
previously.9 The steady-state kinetic parameters (Km and kcat) were
determined under initial-rate conditions using Lineweaver–Burk plot.
Enterobacterial repetitive consensus (ERIC)-PCR
ERIC-PCRs were performed in 50 mL volumes containing 10 ng
of genomic DNA from three clinical E. coli isolates containing the
blaCTX-M-12 gene, 4 mM MgCl2, 50 pM of each primer [ERIC-1R
(50-ATGTAAGCTCCTGGGGATTCAC-30) and ERIC-2 (50-AAGT-
AAGTGACTGGGGTGAGCG-30)], 1.25 U of TaKaRa Ex Taq
polymerase (TaKaRa, Otsa, Shiga, Japan), 0.2 mM each of dATP,
dCTP, dGTP and dTTP in 25 mM TAPS [N-Tris(hydroxy)methyl-3-
amino-propane sulphonic acid, pH 9.3], 50 mM KCl and 1 mM
2-mercaptoethanol. Amplification was carried out as described
previously10 and amplicons were analysed by gel electrophoresis.
Nucleotide sequence accession numbers
The nucleotide sequence data reported in this paper are available in
the GenBank nucleotide database under accession numbers
DQ658220, DQ658221 and DQ658222.
Results and discussion
E. coli SME3, SSE5 and SCE4 were isolated from urine
specimens of three patients hospitalized at three different
hospitals in Seoul and Gumi, Korea, in 2004. The isolates were
resistant to cefotaxime, but susceptible to ceftazidime and all
exhibited positive results in the DDS test, indicating ESBL
production.
PCR amplifications using primers specific for ESBL-encoding
genes revealed that all three E. coli isolates possessed both
blaTEM and blaCTX-M-1-type genes. Sequences of the blaTEM PCR
amplicons were 100% identical to the blaTEM-1 sequence.
Sequence data from the amplicons of the CTX-M-1 cluster
indicated the presence of CTX-M-12 (GenBank accession no.
AF305837). An ISEcp1 insertion sequence, which may play a role
in the mobilization of the blaCTX-M genes by a transcriptional
mechanism by recognizing a variety of DNA sequences as
right inverted repeats (IRs),11 was located 49 bp upstream of
blaCTX-M-12 in all three E. coli isolates. ISEcp1 possessed two
imperfect IRs, the left IR (CCTAGATTCTACGTCAGT) and the
right IR (ACACACGTGGAATTTAGG), made of 18 bp with
14 of these 18 bp being complementary. A putative promoter
1258
Bae et al.
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 18, 2014
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
consisting of the –10 (TACAAT) and –35 (TTGAAA) regions
was observed within the 30 non-coding sequence of ISEcp1.
IEF of the partially purified b-lactamase of E. coli BL21(DE3)
carrying plasmid pET30a-CTX-M-12 revealed a band with a
pI value of 9.0. The kinetic parameters for the CTX-M-12
b-lactamase showed that it had activity against benzylpenicillin,
cefaloridine and cefotaxime (Table 1). The catalytic efficiency
(kcat/Km) of CTX-M-12 against cefotaxime (3.130 mM–1 s–1)
was much higher than that against ceftazidime (0.004 mM–1 s–1).
All three E. coli isolates contained a plasmid with molecular
sizes of 18 kbp containing blaCTX-M-12 and blaTEM-1 genes. But
ERIC-PCRof the threeE. coli isolates proved that these strainswere
not clonal (data not shown), indicating that horizontal transfer of the
blaCTX-M-12 gene had occurred and suggesting the possibility of
further spread of this gene in the future. Despite repeated attempts,
only one (SCE4) among threeE. coli isolates transferred the plasmid
(pSCE4) to the E. coli J53 AzideR recipient bymating experiments.
Agar dilution MIC testing confirmed that all three E. coli
isolates were highly resistant to ampicillin, intermediate or
resistant to aztreonam, cefoxitin, cefotaxime and cefepime, and
susceptible to ceftazidime and imipenem (Table 2). The b-lactam
resistance phenotypes of the transconjugant (E. coli trcSCE4)
were almost identical to those of the parent strain. In the Kenya
study, the CTX-M-12-producing K. pneumoniae isolates were
resistant to cefotaxime (MIC 24 mg/L by Etest), but the presence
of clavulanic acid lowered the MIC of the drug 750 times to
0.032 mg/L.3 In our cases, however, clavulanic acid restored the
activities of cefotaxime in E. coli BL21(DE3) carrying plasmid
pET30a-CTX-M-12 only, but not in both the clinical E. coli
isolates and the E. coli transconjugant.
In summary, this work shows that CTX-M-12 has now
emerged in Korea, in addition to its recent description in
China.5 Our kinetic characterizations show that CTX-M-12 was
more active against cefotaxime than against ceftazidime, and we
have also demonstrated the association of the blaCTX-M-12 with an
upstream ISEcp1 element.
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Table 1. Kinetic parameters of CTX-M-12 b-lactamase against
substrates
Compound Km (mM) kcat (s–1) kcat/Km (mM–1 s–1)
Benzylpenicillin 32.90 669.30 20.343
Cefaloridine 268.70 198.40 0.738
Cefalotin 806.00 146.40 0.182
Cefoxitin 25.30 0.02 0.001
Ceftazidime 464.50 1.80 0.004
Cefotaxime 99.70 312.10 3.130
Aztreonam 177.40 17.10 0.096
Imipenem ND 0.01 ND
ND, not determined.
Table 2. MICs of b-lactams for CTX-M-12 ESBL-producing
clinical E. coli isolates, E. coli trcSCE4 and E. coli BL21(DE3)
carrying plasmid pET30a-CTX-M-12
MICs (mg/L)
Antibiotica
E. coli
SME3b
E. coli
SSE5b
E. coli
SCE4b
E. coli
trcSCE4c
E. coli
trfSCE4d
Ampicillin >256 >256 >256 >256 >256
Cefoxitin 64 16 16 16 2
Aztreonam 16 32 32 128 0.25
Ceftazidime 4 2 4 16 0.06
Ceftazidime + CLA 2 1 1 8 0.06
Cefotaxime 32 64 64 256 32
Cefotaxime + CLA 8 32 32 128 0.06
Cefepime 16 32 32 128 4
Cefepime + CLA 4 16 8 64 0.06
Imipenem 0.12 0.12 0.12 0.25 0.25
aClavulanic acid (CLA) at a fixed concentration of 4 mg/L.
bClinical E. coli isolates containing the blaCTX-M-12 gene.
cE. coli trcSCE4 (transconjugant), E. coli J53 AzideR carrying plasmid pSCE4.
dE. coli trfSCE4 (transformant), E. coli BL21(DE3) carrying plasmid pET30a-
CTX-M-12.
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